news

On February 28, 2026, the 34th China (Nanjing) Community Health Forum was grandly opened at the Nanjing International Expo Center. The event was bustling with activity and booths, showcasing cutting-edge health products and innovative technologies, demonstrating the vibrant vitality of the health industry.

As a council member of the China Health Care Association and the leading unit of the Peptide and Health Industry Branch of the China Health Care Association, Tai Ai Peptide Group was invited to participate in the exhibition and successfully held the seminar on “Opportunities and Challenges of the Peptide Industry in an Aging Society”, building a high-level platform for industry exchange.

△ Speech by Ms. Wu Xia, Chairwoman of Tai Ai Peptide Group

At the seminar, Ms. Wu Xia, Chairwoman of Tai Ai Peptide Group, delivered the opening speech. She stated that “Healthy China” has risen to the level of a national strategy, and against the backdrop of a deeply aging population, the health industry is ushering in an unprecedented development opportunity. Tai Ai Peptide, inheriting the spirit of “Life Never Ceases, Scientific Research Never Stops,” adheres to the principle of upholding integrity and innovation. Leveraging core technologies such as bio-enzymatic hydrolysis and targeted enzymatic cleavage, it accurately explores the health value of peptides, contributing to the peptide-based innovation of traditional Chinese medicine and providing strong support for healthy aging.

△ Liu Dongli, former director of the Nutrition Department of the Air Force General Hospital

△ Yu Zhimin, researcher at the China Academy of Chinese Medical Sciences

△ Xing Qingli, market supervision and law enforcement expert

△ Dr. Yang Bo, Chief Scientist of Tai Ai Peptide Group

△ Dr. Guo Chunyu, Dean of the Research Institute of Tai Ai Peptide Group

This symposium brought together government leaders, clinical experts, industry leaders, and representatives from the investment community to conduct in-depth discussions on the theme of “The Future Path of the Peptide Industry in the Silver Economy.” In the keynote speech session, experts and scholars interpreted core issues such as the health needs of the aging population and the application potential of bioactive peptides; the policy forum focused on the innovation path of peptide products, with drug regulatory and market supervision experts engaging in dialogue and exchange with enterprise representatives; and the parallel forums addressed bottlenecks in industry development from the dual dimensions of technological innovation transformation and market application leadership.

At the conference, Tai Ai Peptide Group launched its core new products, detailed its scientific research and innovation highlights, and released key consensus points from the seminar on “Promoting the Peptide Industry to Support Healthy Aging.” The seminar was moderated by Chen Ying, Dean of the Tai Ai Peptide Group Business School. The successful participation in the exhibition and the seminar not only demonstrated Tai Ai Peptide’s technological innovation capabilities but also established a collaborative platform for industry-academia-research collaboration, injecting new momentum into the high-quality development of the peptide industry.